Ladenburg Thalmann Financial Services’s ETF Series Solutions Trust Range Cancer Therapeutics ETF CNCR Stock Holding History

Ladenburg Thalmann Financial Services’s Portfolio CNCR Stock Details CNCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	$16K	Hold	682	–	–	﹤0.01%	4244
2019 Q3	$12K	Hold	682	–	–	﹤0.01%	4294
2019 Q2	$15K	Sell	682 -500	-42%	-$10.3K	﹤0.01%	4219
2019 Q1	$25K	Hold	1,182	–	–	﹤0.01%	3849
2018 Q4	$22K	Sell	1,182 -100	-8%	-$2.08K	﹤0.01%	3805
2018 Q3	$31K	Buy	1,282 +681	+113%	+$16.7K	﹤0.01%	3625
2018 Q2	$17K	Hold	601	–	–	﹤0.01%	3918
2018 Q1	$17K	Buy	601 +541	+902%	+$15.3K	﹤0.01%	3918
2017 Q4	$1K	Hold	60	–	–	﹤0.01%	4881
2017 Q3	$2K	Hold	60	–	–	﹤0.01%	4651
2017 Q2	$1K	Hold	60	–	–	﹤0.01%	4711
2017 Q1	$1K	Hold	60	–	–	﹤0.01%	4686
2016 Q4	$1K	Sell	60 -1,000	-94%	-$23K	﹤0.01%	4631
2016 Q3	$27K	Buy	1,060 +60	+6%	+$1.48K	﹤0.01%	3196
2016 Q2	$23K	Hold	1,000	–	–	﹤0.01%	3246
2016 Q1	$22K	Hold	1,000	–	–	﹤0.01%	3184
2015 Q4	$29K	Buy	+1,000	New	+$28.8K	﹤0.01%	2953

Other funds holding CNCR

BCWM LLC Overland Park, Kansas $353M AUM 20.1% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

PAG

Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

AWA

Arete Wealth Advisors Chicago, Illinois $1.33B AUM 25.12% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Ladenburg Thalmann Financial Services's CNCR Position: Q4 2019 in Review

Ladenburg Thalmann Financial Services held its ETF Series Solutions Trust Range Cancer Therapeutics ETF (CNCR) position steady in Q4 2019 at 682 shares worth $16K. The position accounts for ﹤0.01% of the portfolio, ranked #4244.

Ladenburg Thalmann Financial Services first reported a position in CNCR in Q4 2015 and has held it in 17 quarters since. The position peaked at $31K in Q3 2018. 23 funds tracked by Wall St. Rank hold CNCR as of Q4 2019.

Ladenburg Thalmann Financial Services held 682 shares of ETF Series Solutions Trust Range Cancer Therapeutics ETF worth $16K as of Q4 2019.
Ladenburg Thalmann Financial Services left its ETF Series Solutions Trust Range Cancer Therapeutics ETF share count unchanged in Q4 2019.
ETF Series Solutions Trust Range Cancer Therapeutics ETF made up ﹤0.01% of Ladenburg Thalmann Financial Services's portfolio in Q4 2019, its #4244 holding.
Ladenburg Thalmann Financial Services first reported a position in ETF Series Solutions Trust Range Cancer Therapeutics ETF in Q4 2015 and has held it in 17 quarters since.
Ladenburg Thalmann Financial Services's ETF Series Solutions Trust Range Cancer Therapeutics ETF position peaked at $31K in Q3 2018.
23 funds tracked by Wall St. Rank held ETF Series Solutions Trust Range Cancer Therapeutics ETF as of Q4 2019.

Based on Ladenburg Thalmann Financial Services's 13F filing for Q4 2019, filed 14 Feb 2020.